Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Pre-market:
| Previous close | 6.20 |
| Open | 5.67 |
| Bid | 6.90 x 1000 |
| Ask | 6.91 x 1400 |
| Day's range | 5.65 - 7.17 |
| 52-week range | 2.11 - 18.72 |
| Volume | |
| Avg. volume | 415,718 |
| Market cap | 865.692M |
| Beta (5Y monthly) | 2.14 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.42 |
| Earnings date | 08 May 2023 - 12 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.00 |
- PR Newswire
Corbus Pharmaceuticals Data on CRB-601 avβ8 Blocking Antibody Accepted for Presentation at the America Association for Cancer Research Annual Meeting
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that an abstract highlighting pre-clinical data for CRB-601, its avβ8 blocking antibody, has been accepted for presentation at a poster at the 2023 American Association for Cancer Research (AACR) annual meeting, to be held April 14-19, 2023 in Orlando, Fl.
- PR Newswire
Corbus Pharmaceuticals Reports Fourth Quarter 2022 and Year-End Financial Results and Provides Corporate Update
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today provided a corporate update and reported financial results for the fourth quarter and year-end of 2022.
- PR Newswire
Corbus Pharmaceuticals Expands Board of Directors with Appointment of Yong Ben, M.D., MBA
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced the appointment of Yong Ben, M.D., MBA, to the Company's Board of Directors.
